Skip to Main Content

Hello, everyone, and how are you today? A warm and shiny sun is enveloping the Pharmalot campus this morning, where things have quieted down now that the short person has left for the summer gig and the official mascots are happily snoozing in their recliners. As for us, we are busy foraging for interesting items and, of course, quaffing some cups of stimulation. Feel free to join in. Meanwhile, here is the latest menu of tidbits. We hope you have a grand day or, at least, survive. And if you do, by all means, keep in touch …

A long-awaited AstraZeneca trial combining two immunotherapies failed to help patients with advanced lung cancer, STAT says. The news sent its stock plunging and further pressures chief executive Pascal Soriot to rebuild the pipeline after spurning a $118 billion takeover bid by Pfizer in 2014. Uncertainty about the outcome prompted rumors Soriot was leaving for Teva Pharmaceuticals, but he would only say that “I am not a quitter,” The Guardian tells us.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!